Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (300)	9/8/2003 1:06:56 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion And Lilly Enter Into Research Services Pact DOW JONES NEWSWIRES NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) and Eli Lilly & Co. (LLY) signed a research agreement related to Triapine and Gemzar, their respective anticancer agents. In a press release Monday, Vion said the agreement relates to the measurement of the expression of several genes in tumor tissue and blood samples from patients participating in Vion's phase II trials of the combination therapy in non-small-cell lung cancer and pancreatic cancer. Vion said the studies it's conducting may provide more understanding of the genetic makeup of patients and their tumors that determine responsiveness to Gemzar and also could identify populations of patients that could benefit from the addition of Triapine to Gemzar. In June, Vion found that Triapine achieved serum concentrations capable of enhancing gemcitabine activity in tumor cells, while its leukemia agent was well-tolerated, according to phase I trials. Triapine was studied in combination with Gemzar, the brand name of gemcitabine, a nucleoside analogue for the treatment of certain solid tumors. Shares of Vion closed Friday at $1.62, up 14 cents, or 9.5%, in Nasdaq trading. The stock last traded at $2.47, according to an Instinet spokesman. Company Web site: vionpharm.com